- Oramed announces publication in diabetes journal
- UnitedHealth: Cost of diabetes could be $3.35 trillion by 2020
- Decision Resources: Type 2 diabetes market in China to nearly double by 2014
- Walgreens' Pegus to discuss impact of diabetes management on healthcare costs
- Rite Aid takes a bite out of obesity; relaunches weight-loss program for New Year
INDIANAPOLIS — Drug makers Boehringer Ingelheim and Eli Lilly have created a new online educational program for people with Type 2 diabetes.
The companies, which have had a deal to develop drugs for diabetes since January 2011 and co-market the drugs Tradjenta (linagliptin) and Jentadueto (linagliptin and metformin), announced Thursday the creation of My Well Planner, a lifestyle-improvement program for adults with the disease.
The program is a free resource for adults with Type 2 diabetes modeled on a behavioral-change approach that offers customized educational content and is designed to help patients and their healthcare providers set small lifestyle goals, featuring topics like general information about the disease, better eating habits, physical activity and others, the companies said.